

Resource Summary Report

Generated by [NIF](#) on Sep 8, 2026

C0804

RRID:CVCL_K562

Type: Cell Line

Proper Citation

ECACC Cat# 94090127, RRID:CVCL_K562

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_K562

Proper Citation: ECACC Cat# 94090127, RRID:CVCL_K562

Description: Cell line C0804 is a Transformed cell line with a species of origin Homo sapiens (Human)

Sex: Male

Comments: Population: Caucasian., Part of: ECACC randomly selected UK Caucasian blood donors cell line selection.

Category: Transformed cell line

Organism: Homo sapiens (Human)

Name: C0804

Cross References: ECACC:94090127, Wikidata:Q54807578

ID: CVCL_K562

Vendor: ECACC

Catalog Number: 94090127

Record Creation Time: 20220427T215426+0000

Record Last Update: 20260905T174445+0000

Ratings and Alerts

No rating or validation information has been found for C0804.

Warning: Discontinued: ECACC; 94090127

Population: Caucasian., Part of: ECACC randomly selected UK Caucasian blood donors cell line selection.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Yuan DJ, et al. (2026) Genotype-to-Phenotype Mapping of Somatic Clonal Mosaicism via Single-Cell Co-Capture of DNA Mutations and mRNA Transcripts. *Cancer discovery*, 16(4), 721.

Beke F, et al. (2026) L-type voltage-gated Ca²⁺ channels control T cell killing via non-canonical Hedgehog signalling. *EMBO reports*, 27(13), 3689.

Calescibetta A, et al. (2026) Combining lenalidomide with IL-2 family of cytokines enhances activating receptor and perforin/granzyme expression in NK cells. *PloS one*, 21(3), e0344471.

Wang Y, et al. (2026) Identification of CADM1 as an Immunotherapeutic Target and Evaluation of a Novel CADM1-Targeting Antibody-Drug Conjugate in Preclinical Osteosarcoma Models. *Molecular cancer therapeutics*, 25(6), 881.

Lou E, et al. (2026) Super-Enhancer-Driven SOX4/SMAD3 Mediate Membrane Remodeling by Regulating Phospholipid Metabolism to Accelerate Leukemia Progression. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(24), e12332.

Skowronek P, et al. (2025) An accessible workflow for high-sensitivity proteomics using parallel accumulation-serial fragmentation (PASEF). *Nature protocols*, 20(6), 1700.

Moares N, et al. (2025) Dual targeting of BCMA and SLAMF7 with the CARtein system: chimeric antigen receptors with intein-mediated splicing elicit specific T cell activation against multiple myeloma. *Frontiers in immunology*, 16, 1613222.

Huber A, et al. (2025) Phenotypic and epigenetic profiles of circulating NK cells in spontaneous HIV-1 controllers. *EBioMedicine*, 120, 105948.

Qiao X, et al. (2024) Diversifying the anthracycline class of anti-cancer drugs identifies aclarubicin for superior survival of acute myeloid leukemia patients. *Molecular cancer*, 23(1), 120.

Lei W, et al. (2024) Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. *Cell discovery*, 10(1), 5.

Demirkiran N, et al. (2024) Study of the effect of sFRP1 protein on molecules involved in the regulation of DNA methylation in CML cell line. Medical oncology (Northwood, London, England), 41(5), 109.